What are the potential risks and benefits of this intermittent abiraterone approach compared to continuous...

Here is some information on the potential risks and benefits of intermittent vs continuous abiraterone treatment for prostate cancer, based on guidelines from trusted medical sources:

According to the NCCN Guidelines for Prostate Cancer, intermittent androgen deprivation therapy (ADT) approaches like intermittent abiraterone may reduce side effects compared to continuous ADT. However, they note that the long-term efficacy of intermittent ADT compared to continuous ADT remains unclear based on current evidence. Close monitoring of PSA and testosterone levels is recommended during off-treatment periods.

The American Urological Association guidelines state that intermittent ADT may be offered as an alternative to continuous ADT for patients with non-metastatic or metastatic prostate cancer. Potential benefits include decreased side effects and improved quality of life during off-treatment intervals. However, they emphasize there is no clear evidence that survival with intermittent ADT is equivalent to continuous ADT.

To monitor for any changes in your cancer during the abiraterone treatment breaks, the NCCN recommends:

• Regular PSA testing every 3-6 months
• Periodic imaging with CT, MRI or bone scans as clinically indicated based on symptoms and PSA trends
• Tracking testosterone levels to ensure adequate suppression during treatment periods

It's important to have close follow-up with your oncologist during intermittent therapy to catch any signs of disease progression early. Always consult with your doctor about the best treatment approach and monitoring plan for your individual situation. They can provide personalized guidance on balancing the risks and benefits of intermittent vs continuous therapy for your prostate cancer.